Evidence map›Paper›PMID 20519635›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2010

Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation.

Ana Luisa Kadekaro, Sancy Leachman, Renny J Kavanagh, Viki Swope, Pamela Cassidy, Dorothy Supp, Maureen Sartor, Sandy Schwemberger, George Babcock, Kazumasa Wakamatsu and 6 more

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Unique Features of Melanoma Risk and Diagnosis in Red-Haired Populations.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. An overview of benefits and risks of chronic melanocortin-1 receptor activation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Review
  9. Review
  10. Contribution of Keratinocytes in Skin Cancer Initiation and Progression.International journal of molecular sciences · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Chemiexcitation: Mammalian Photochemistry in the DarkPhotochemistry and photobiology · 2023
    Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Ana Luisa KadekaroDepartment of Dermatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0592, USA.
Sancy Leachman
Renny J Kavanagh
Viki Swope
Pamela Cassidy
Dorothy Supp
Maureen Sartor
Sandy Schwemberger
George Babcock
Kazumasa Wakamatsu
Shosuke Ito
Amy Koshoffer
Raymond E Boissy
Prashiela Manga
Richard A Sturm
Zalfa A Abdel-Malek
University of Cincinnati · USFujita Health University · JPUniversity of Utah · USBurn Institute · USCincinnati Health Department · USNew York University · USShriners Hospitals for Children - Cincinnati · USUniversity of Queensland · AU

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI YADAV, JAGJIT S · 1992 to 2022
$35.4M
Signaling Pathways for UV-Induced Melanogenic ResponsesR01ES009110 · NIEHS · UNIVERSITY OF CINCINNATI · PI ABDEL-MALEK, ZALFA · 1998 to 2012
$3.8M
Impact of MC1R Functional Variants on the DNA Damage Response of Human MelanocyteR01ES017561 · NIEHS · UNIVERSITY OF CINCINNATI · PI ABDEL-MALEK, ZALFA, LEACHMAN, SANCY ANN · 2009 to 2013
$1.6M
NIEHS NIH HHS P30 ES006096NIEHS NIH HHS P30 ES06096NIEHS NIH HHS R011ES017561NIEHS NIH HHS R01 ES009110NIEHS NIH HHS R01ES009110NIEHS NIH HHS R01 ES017561
6 · The paper itself

Abstract

The melanocortin 1 receptor gene is a main determinant of human pigmentation, and a melanoma susceptibility gene, because its variants that are strongly associated with red hair color increase melanoma risk. To test experimentally the association between melanocortin 1 receptor genotype and melanoma susceptibility, we compared the responses of primary human melanocyte cultures naturally expressing different melanocortin 1 receptor variants to α-melanocortin and ultraviolet radiation. We found that expression of 2 red hair variants abolished the response to α-melanocortin and its photoprotective effects, evidenced by lack of functional coupling of the receptor, and absence of reduction in ultraviolet radiation-induced hydrogen peroxide generation or enhancement of repair of DNA photoproducts, respectively. These variants had different heterozygous effects on receptor function. Microarray data confirmed the observed differences in responses of melanocytes with functional vs. nonfunctional receptor to α-melanocortin and ultraviolet radiation, and identified DNA repair and antioxidant genes that are modulated by α-melanocortin. Our findings highlight the molecular mechanisms by which the melanocortin 1 receptor genotype controls genomic stability of and the mutagenic effect of ultraviolet radiation on human melanocytes.

Indexed as

Ultraviolet RaysCells, CulturedGenotypeHumansMelanocytesReceptor, Melanocortin, Type 1Receptor, Melanocortin, Type 1

Identifiers

PMID20519635
PMCPMC3229421
OpenAlexW2022732422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.